FDA
-
-
-
-
-
-
-
Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
-
-
-
-
-
-
-
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia
-
-
-
-
-
-
-
Biomea Fusion, Inc. (BMEA): FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials (Earlier)
-
-
-
-
-
-
-
BMEA ANNOUNCEMENT: If You Have Suffered Losses in Biomea Fusion, Inc. (NASDAQ: BMEA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
-
-
-
-
-
-
-
Biomea Fusion (BMEA) Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
-
-
-
-
-
-
-
Biomea Fusion (BMEA) Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study
-
-
-
-
-
-
-
Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

